Science Explorer Interactive view Map
Company · San Diego · United States

SignalRx Pharmaceuticals (United States)

Research works
110
▲ 25% vs 2013–17
Citations
8.1k
73.6 per fractional work
Top-10% rate
0.0%
record average 16.5%
Open access
29%
world 28%

Not ranked overall: SignalRx Pharmaceuticals (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

What does SignalRx Pharmaceuticals (United States) specialise in?

Where its research is concentrated relative to its size: Molecular Biology takes 5.6× the share of its output that it takes of world research.

  1. Molecular BiologySubfield · 24.5 works5.6×
← less than its size predictsmore →

Location quotient, a volume reading rather than an impact one. It surfaces small, lopsided specialities.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Which keywords describe research at SignalRx Pharmaceuticals (United States)?

By fractional works in all years, weighted toward what it does more of than the world: Inflammation, Cancer, Signaling, Immunity, Immune Response, Regulation, Cancer Therapy and NF-?B.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Inflammation23▲ 9.0×23 topics
  2. Cancer22▲ 15×22 topics
  3. Signaling12▲ 95×3 topics
  4. Immunity10▲ 28×5 topics
  5. Immune Response10▲ 14×8 topics
  6. Regulation10▲ 15×4 topics
  7. Cancer Therapy9▲ 13×12 topics
  8. NF-?B9▲ 268×1 topic
  9. ubiquitination9▲ 412×1 topic
  10. Transcriptional Regulation7▲ 27×6 topics
  11. Tumor Microenvironment7▲ 18×5 topics
  12. Anticancer Agents6▲ 22×5 topics
  13. IL-66▲ 164×1 topic
  14. STAT36▲ 164×1 topic
  15. Medicinal Chemistry6▲ 14×5 topics
  16. Oncogenic Mutations5▲ 98×2 topics
  17. Apoptosis5▲ 11×9 topics
  18. Drug Discovery5▲ 11×5 topics
  19. Heterocyclic Compounds4▲ 25×3 topics
  20. Synthesis4▲ 6.7×7 topics
  21. Pattern Recognition Receptors4▲ 25×2 topics
  22. Cancer Progression3▲ 12×4 topics
  23. Foldamers3▲ 35×1 topic
  24. Peptide Synthesis3▲ 35×1 topic
  25. Signal Transduction3▲ 12×4 topics
  26. Tubulin Inhibitors3▲ 54×1 topic
  27. Vascular Targeting Agents3▲ 54×1 topic
  28. Innate Immunity3▲ 7.0×5 topics
  29. Reactive Oxygen Species3▲ 4.9×4 topics
  30. BRAF gene3▲ 136×1 topic
  31. Cell Migration3▲ 28×2 topics
  32. MAP Kinase3▲ 136×1 topic
  33. Antimicrobial Activity2▲ 12×3 topics
  34. Cell Signaling2▲ 6.6×7 topics
  35. Innate Antiviral Responses2▲ 32×1 topic
  36. Nuclear Receptors2▲ 12×4 topics
  37. Toll-like Receptors2▲ 13×1 topic
  38. Calcium Signaling2▲ 16×2 topics
  39. Protein Kinases2▲ 73×1 topic
  40. Ras Signaling2▲ 73×1 topic

Which research topics does SignalRx Pharmaceuticals (United States) publish most on?

By volume in 2022–2025: MicroRNA in disease regulation, Long-Term Effects of COVID-19, Respiratory Support and Mechanisms and Advanced Breast Cancer Therapies.

  1. 1 MicroRNA in disease regulation Cancer Research 0 works
  2. 2 Long-Term Effects of COVID-19 Neurology 0 works
  3. 3 Respiratory Support and Mechanisms Pulmonary and Respiratory Medicine 0 works
  4. 4 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 0 works
  5. 5 Extracellular vesicles in disease Molecular Biology 0 works
  6. 6 COVID-19 Clinical Research Studies Infectious Diseases 0 works
  7. 7 Lung Cancer Research Studies Oncology 0 works
  8. 8 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 0 works
  9. 9 Histone Deacetylase Inhibitors Research Molecular Biology 0 works
  10. 10 Wnt/β-catenin signaling in development and cancer Molecular Biology 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available29.1%not open70.9%

World: 28% of research is openly available.

with international co-authors13.7%domestic only86.3%

World: 19% is written across borders.

How has SignalRx Pharmaceuticals (United States)'s research output changed?

Output in 2018–2022 was 25% higher than in 2013–2017.

1990200020102020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in San Diego

All research institutions in San Diego

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.